Bio Impact Capital LLC Crinetics Pharmaceuticals, Inc. Transaction History

Bio Impact Capital LLC

$641 Million
Q3 2024

A detailed history of Bio Impact Capital LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Bio Impact Capital LLC holds 525,845 shares of CRNX stock, worth $29.1 Million. This represents 4.19% of its overall portfolio holdings.

Number of Shares

525,845

Previous 557,184 5.62%

Holding current value

$29.1 Million

Previous $25 Million 7.63%

% of portfolio

4.19%

Previous 4.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$43.83 - $54.98 $1.37 Million - $1.72 Million	-31,339 Reduced 5.62%	525,845 $26.9 Million
Q2 2024 Aug 14, 2024	BUY	$42.12 - $51.91 $3.23 Million - $3.98 Million	76,596 Added 15.94%	557,184 $25 Million
Q1 2024 May 15, 2024	BUY	$34.76 - $46.81 $81,825 - $110,190	2,354 Added 0.49%	480,588 $22.5 Million
Q4 2023 Feb 13, 2024	SELL	$25.62 - $37.07 $20,982 - $30,360	-819 Reduced 0.17%	478,234 $17 Million
Q2 2023 Aug 14, 2023	BUY	$15.73 - $23.6 $1.87 Million - $2.8 Million	118,661 Added 32.93%	479,053 $8.63 Million
Q1 2023 May 12, 2023	SELL	$15.31 - $21.1 $172,191 - $237,311	-11,247 Reduced 3.03%	360,392 $5.79 Million
Q4 2022 Feb 14, 2023	BUY	$15.49 - $19.05 $107,330 - $131,997	6,929 Added 1.9%	371,639 $6.8 Million
Q3 2022 Nov 14, 2022	SELL	$18.11 - $22.37 $35,604 - $43,979	-1,966 Reduced 0.54%	364,710 $7.16 Million
Q1 2022 May 13, 2022	SELL	$17.15 - $28.31 $224,939 - $371,313	-13,116 Reduced 3.45%	366,676 $8.05 Million
Q4 2021 Feb 11, 2022	BUY	$19.35 - $28.41 $1.58 Million - $2.31 Million	81,400 Added 27.28%	379,792 $10.8 Million
Q3 2021 Nov 15, 2021	BUY	$16.88 - $25.23 $5.04 Million - $7.53 Million	298,392 New	298,392 $6.28 Million

Others Institutions Holding CRNX

# of Institutions

242

Shares Held

79.6M

Call Options Held

23.3K

Put Options Held

44.3K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.98B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bio Impact Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bio Impact Capital LLC with notifications on news.

Account

Bio Impact Capital LLC Crinetics Pharmaceuticals, Inc. Transaction History